Prebiotic Oligosaccharides: Comparative Evaluation Using In Vitro Cultures of Infants' Fecal Microbiomes

J Stiverson1, T Williams2, J Chen1

  • 1Department of Animal Sciences, The Ohio State University, Columbus, Ohio, USA.

Insights

Galacto-oligosaccharide (GOS) supplementation in infant formula significantly boosted beneficial Bifidobacterium growth, including Bifidobacterium longum. This prebiotic effect also led to higher acetic acid levels and a potential reduction in E. coli, suggesting improved infant gut health.

Area of Science:

  • Microbiology
  • Nutritional Science
  • Pediatrics

Background:

  • The infant gut microbiome plays a crucial role in health and development.
  • Prebiotics are non-digestible food ingredients that selectively stimulate beneficial bacteria.
  • Galacto-oligosaccharides (GOS) are commonly used prebiotics in infant nutrition.

Purpose of the Study:

  • To evaluate the bifidogenic effects of commonly used prebiotic products in infant fecal cultures.
  • To compare the efficacy of galacto-oligosaccharide (GOS), inulin (IN), and oligofructose-inulin (OF-IN) on gut microbiota composition.
  • To assess the impact of prebiotics on specific bacterial groups like Bifidobacterium and Escherichia coli.

Main Methods:

  • In vitro incubation of infant fecal samples (from breast milk and formula-fed infants) with different prebiotic products.
  • Quantification of bacterial populations (total bacteria, Bifidobacterium, Bacteroides, Bifidobacterium longum, Escherichia coli) using quantitative PCR (qPCR).
  • Enumeration of Bifidobacterium on selective agar, identification via 16S rRNA gene sequencing, and measurement of volatile fatty acids (VFA) and pH.

Main Results:

  • Galacto-oligosaccharide (GOS) products, alone or combined with inulin, significantly increased total Bifidobacterium and Bifidobacterium longum abundance.
  • Oligofructose-inulin (OF-IN) also enhanced Bifidobacterium and Bifidobacterium longum levels.
  • Increased acetic acid concentrations and a trend towards lower Escherichia coli levels and pH were observed with GOS supplementation.

Conclusions:

  • Galacto-oligosaccharide (GOS) demonstrated a potent bifidogenic effect and inhibited Escherichia coli growth at studied concentrations.
  • Supplementation of infant formula with GOS may promote a healthier gut microbiota in infants.
  • These findings support the potential benefits of GOS for infant gut health.

Related Concept Videos

Development of Human Microbiota01:30

Development of Human Microbiota

The human microbiota begins developing at birth and undergoes continual change as we age. Infancy marks a critical period of microbial sensitivity, offering a “window of opportunity” during which beneficial microbes help mature the immune system. By age three, children typically develop a more stable and diverse microbial community. Newborns acquire microbes from their immediate environment; vaginal delivery favors maternal vaginal microbes, while cesarean births favor microbes from...
58
Development of the Oral Microbiota01:28

Development of the Oral Microbiota

The establishment of the oral microbiome begins before birth, challenging the long-held belief that the fetal oral cavity is sterile. The presence of oral microbes such as Streptococcus and Fusobacterium in amniotic fluid suggests that microbial exposure may occur in utero, potentially through translocation from the maternal oral or gastrointestinal tract. This early colonization primes the neonatal immune system and sets the stage for subsequent microbial succession. Maternal health,...
58
Probiotics01:22

Probiotics

Probiotics are live, non-pathogenic microorganisms that confer health benefits by modulating the gut microbiota. The human gastrointestinal tract harbors a complex microbial ecosystem, and the balance of this microbiota is crucial for digestive and systemic health. Among the most extensively studied and utilized probiotics are species formerly classified within the genera Lactobacillus and Bifidobacterium. These organisms not only naturally colonize the human gut but are also consumed through...
286
Introduction to the Human Microbiota01:22

Introduction to the Human Microbiota

Microorganisms colonize various regions of the human body, including the mouth, nasal passages, throat, stomach, intestines, urogenital tract, and skin. The total number of microbial cells is estimated to range from 10¹³ to 10¹⁴—comparable to, or exceeding, the number of human somatic cells. This host–microbiome relationship has led to the conceptualization of humans as supraorganisms, wherein microbial communities perform vital roles in development, immunity,...
138
Microbiota of the Stomach and Small Intestine01:27

Microbiota of the Stomach and Small Intestine

The human gastrointestinal (GI) tract is characterized by distinct physicochemical conditions that shape its microbial communities. Among these, the stomach presents a particularly challenging environment for microbial colonization due to its highly acidic pH, ranging from 1 to 3. This extreme acidity effectively limits microbial density. However, certain acid-tolerant microorganisms are capable of surviving in this niche. Notably, Helicobacter pylori can colonize the gastric mucosa,...
72
Microbiota of the Large Intestine01:27

Microbiota of the Large Intestine

The large intestine hosts the most densely populated microbial ecosystem in the human body. This complex community primarily consists of anaerobic bacteria, with Bacillota (formerly Firmicutes) and Bacteroidota (formerly Bacteroidetes) as the predominant groups. The distribution of these microbes varies along different sections of the large intestine, influenced by local environmental factors such as oxygen availability and nutrient composition.The cecum, located at the beginning of the large...
89